PTO/SE/08a (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are

A Nationalitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANTS

(use as many sheets as necessary)

Sheet of

requied to respond to a conscion.	of information unless it contains a	Valid Civils control number
	Complete if Known	
Application Number	10/824,731	
Filing Date	April 15, 2004	
First Named Inventor	James Patrick D	นทก
Art Unit	T014 1626	
Examiner Name	Not yet assigned	G.Shameem
Attorney Docket Number	R0163B-REG	

U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant	
Initials *	No.	Number - Kind Code ² (if known)	MM-DD-YYYY	Criso Document	Passages or Relevant Figures Appear	

		FOR	EIGN PATENT DOC	CUMENTS		
Examiner	Foreign Patent Document	Name of Patentee or	Pages, Columns, Lines,			
Initials*	Cite No. ¹	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T⁰
GS	C1	WO 92/07844 A1	14-May-1992	Pfizer Inc., Groton, CT		
GS	C2	EP 1 052 254 A1	15-Nov-2000	Eisai Co., Ltd. Tokyo, JP		

	·	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
GS	C3	WANDEL, et al, "P-Glycoprotein and Cytochrome P-450 3A Inhibition: Dissociation of Inhibitory Potencies ¹ ", Cancer Research, August 15, 1999, pp 3944-3948, Vol 59:16	
GS	C4	WEBB, et al., "Quinazolines as Adenosine Receptor Antagonists: SAR and Selectivity for A_{28} Receptors", Bioorganic & Medicinal Chemistry , (2003), pp 77-85, Vol 11	
GS	C 5	HESS, et al., "Antihypertensive 2-Amino-4(3H)-quinazolines", Journal of Medicinal Chemistry, (1968), pp 130-136, Vol 11:1	

Examiner /Golam Shameem/ (06/29/200 Considered 06/	/29/2006
--	----------

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 10/824,731 April 15, 2004 Filing Date First Named Inventor James Patrick Dunn 1626 Art Unit

Complete if Known

(use as many sheets as necessary)

Sheet of

Examiner Name	Net yet assigned-
Attorney Docket Number	R0163B-REG

U.S. PATENT DOCUMENTS					
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns.
initials *	No.	Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passage Figur
GS	B1	US-6,476,031	11-05-2002	Scios, Inc.	
		US-			

		FOREIG	N PATENT DO	CUMENTS			
		Foreign Patent Document			Name of Patentee or	Pages, Columns, Lines,	
Examiner Initials*	Cite No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁴	
GS	B2	GB 1,024,908	04-06-1966	Monsanto Chemicals Limited			
				İ			

	L.
Ing to	und to 38

Examiner Signature	/Golam Shameem/ (06/29/2000) Considered	06/29/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file

(and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Doc. #128444V1